INTELLIGENT BIO SOLUTIONS Business Summary

Intelligent Bio Solutions Inc. (INBS) utilizes a high-margin "razor-razorblade" business model centered on its proprietary Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat to detect substances including opiates, cocaine, and cannabis. Revenue is generated through the upfront sale of portable handheld readers and recurring, high-volume transactions of single-use diagnostic cartridges, supplemented by accessories and training services. The company operates across four primary geographic segments—the United Kingdom, Asia Pacific (APAC), the Americas, and Rest of World—with the UK currently serving as the lead revenue engine. INBS competes with medical diagnostic and equipment firms such as Drägerwerk AG, Abbott Laboratories, and PetVivo (PETV), positioning itself as a non-invasive disruptor in the $14.9 billion global drug screening market. The company distinguishes itself through rapid, 10-minute on-site results and is currently scaling international operations while pursuing H2 2026 FDA 510(k) clearance for its planned U.S. market entry. The leadership team is led by President and CEO Harry Simeonidis, a healthcare veteran with over 25 years of experience, including a nine-year tenure as President and CEO of GE Healthcare ANZ and General Manager of Surgery for GE Healthcare Asia Pacific. He is supported by CFO Spiro Sakiris, who brings 35 years of expertise in life science financial reporting and capital markets. The board is chaired by Dr. Steven Boyages, a distinguished clinician and former CEO of the Sydney West Area Health Service, while the company’s technological foundation is rooted in its acquisition of Intelligent Fingerprinting and its relationship with major shareholder Life Science Biosensor Diagnostics Pty Ltd. Key operational leadership includes Doug Heath (VP of Global Sales) and Peter Passaris (VP of Product Development). The firm maintains strong institutional backing, having secured a $10 million private placement in January 2026 from healthcare-focused investors to fund its ongoing FDA 510(k) submission and global expansion.